“Achievement of Treat-to-Target Thresholds With Envudeucitinib, a Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Results from STRIDE and OLE”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s650, https://doi.org/10.25251/8xwzce61.